NCT01250951

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 111 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of deferasirox in patients with MDS, thalassemia and rare anemia patients with transfusion iron overload.

Conditions

• Myelodysplastic Syndrome
• Thalassemia

Interventions

Type	Name	Description
DRUG	Deferasirox

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-07-01
• Completion: 2011-09-01
• First posted: 2010-12-01
• Last updated: 2016-12-12

Locations

2 sites across 1 country: Russia